Cortechs.ai, a top company that develops AI-based neuroimaging software, has announced it has acquired intellectual property from ZepMed, LLC. This includes ZepMed’s patented CT imaging technology and the NeuroAlign CT software. This acquisition adds valuable tools to Cortechs.ai’s offerings and helps the company solidify its role as an innovator in radiology, giving healthcare providers around the world more options.
Health Technology Insights: Bridge to Life Names David Castiglioni CCO for VitaSmart US Launch
Kyle Frye, CEO of Cortechs.ai, shared his excitement about this deal. He said the acquisition builds on ZepMed’s original work and allows Cortechs.ai to continue developing and offering advanced solutions. He called this a key step in the company’s growth and a reflection of its ongoing commitment to helping clinicians worldwide with innovative technology.
Health Technology Insights: OMRON Healthcare Surpasses 400 Million Blood Pressure Monitor Sales
ZepMed is known for its groundbreaking work in CT imaging through NeuroAlign CT, an FDA-cleared Class II software. This software automates important tasks like segmentation, alignment, and reformatting of head CT scans. It improves the accuracy of diagnoses and makes the workflow for radiologists more efficient. The technology helps detect small brain changes more quickly and confidently, which leads to better patient care.
Douglas Bates, MD and co-founder of ZepMed, talked positively about the transition. He was proud of what the company created with NeuroAlign. He felt confident that Cortechs.ai’s team would continue to enhance the software, making it easier to use and expanding its features to help more healthcare professionals and patients around the world.
Daniel Livschutz, Chairman of the Board at Cortechs.ai and Founding Partner at VILAS Ventures, said that acquiring ZepMed’s technology aligns with Cortechs.ai’s mission to provide comprehensive AI-powered tools in neuroimaging and radiology. He noted that this move helps the company offer a more integrated approach to patient care, from monitoring to diagnosis and risk assessment. Livschutz called the acquisition a strategic step that will strengthen Cortechs.ai’s platform, creating a more complete ecosystem that better serves clinicians, patients, and healthcare payers globally.
Health Technology Insights: Lupin Acquires VISUfarma to Boost Global Ophthalmology Business
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
